| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $75M |
Buys | $31,425 | 1 | 50 |
Sells | $31,425 | 1 | 50 |
| Pfeifer Andrea | Chief Executive Officer | 1 | $31,425 | 1 | $31,425 | $0 |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Over the last 12 months, insiders at AC Immune S.A. have bought $31,425 and sold $31,425 worth of AC Immune S.A. stock.
On average, over the past 5 years, insiders at AC Immune S.A. have bought $31,425 and sold $31,425 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Pfeifer Andrea (Chief Executive Officer) — $31,425.
The last purchase of 10,000 shares for transaction amount of $31,425 was made by Pfeifer Andrea (Chief Executive Officer) on 2026‑04‑15.
| Increased Positions | 22 | +53.66% | 2M | +7.16% |
| Decreased Positions | 16 | -39.02% | 610,840 | -2.48% |
| New Positions | 7 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 489,189 | Sold Out |
| Total Postitions | 47 | +14.63% | 26M | +4.68% |